The current price of MESO is $14.27 — it has increased by 1.21% since the previous close. Data as of Nov 6, 2026.
MESO is down 5.37% over the past week, up 2.37% over the past month and down 2.33% over the past year. The price is below its 200-day moving average of $15.33.
Analysts' average 12-month price target for MESO is $39.00, which implies 173.30% upside from the current price. Individual estimates range from $39.00 to $39.00.
Of the 3 analysts covering Mesoblast Limited, 2 rate it a strong buy and 1 rates it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Mesoblast Limited has a market capitalization of $1.85B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Mesoblast Limited posted a loss of $0.13 per share against an estimate of -$0.1055, missing expectations by 23.22%. Upcoming reports are listed in the earnings calendar.
Mesoblast Limited reported revenue of $68.95M in its most recent quarter, which has increased by 342.69% compared with the same quarter a year earlier. Analysts had expected $54.86M.
Mesoblast Limited has not paid any dividends over the past year.
In the latest trading session MESO moved between $13.82 and $14.29, a range of 3.29% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Mesoblast Limited shows a buy rating today and a sell rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Mesoblast Limited is sell. Technical ratings are indicators, not investment advice.
Over the past 52 weeks MESO has traded between $11.89 and $21.50. The current price is 33.63% below its 52-week high.
Figures as of Nov 6, 2026. This information is provided for general purposes only and is not investment advice.